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ABSTRACT 
 
Shikimate dehydrogenase (SDH) is a reversible enzyme catalyzing the reduction 
of 3-dehydroshikimate (3DHS) to shikimate (SKM) utilizing NADPH cofactor in the 
shikimate pathway, a central route for biosynthesis of aromatic amino acids, folates and 
ubiquinones in microogransims, plants and parasites, which renders the enzymes of this 
essential pathway as attractive targets for developing antimicrobials, herbicides and 
antiparasitic agents. In this study, the crystal structure of Mycobacterium tuberculosis 
SDH (MtSDH) was determined in the apo-form and in complex with a ligand, SKM. 
The overall structure of MtSDH contains two structural domains with α/β architecture. 
The N-terminal substrate binding domain and C-terminal cofactor binding domain are 
interconnected by two helices forming an active site groove where catalysis occurs. In 
MtSDH, a series of helices connecting β10 and β11 strands replace a long loop found in 
other known SDH structures and this region may undergo structural changes upon 
cofactor binding. NADP
+
 was modeled reliably in the cofactor binding site to gain 
insight into specific interactions. The analysis reveals that NADP(H) binds in anti 
conformation and in addition to residues in “basic patch”, Ser125 within the glycine rich 
loop may interact with the 2'-phosphate of adenine ribose and form a novel cofactor 
binding microenvironment in SDH family of enzymes. Biochemically, five inhibitors 
identified previously from a high-throughput enzyme assay screen were evaluated. The 
IC50 values of these compounds range from 2.8-4.6 µM. Further investigation indicates 
that these compounds display non-competitive or mixed inhibition mode with both 
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substrate and cofactor. This study is expected to provide better understanding of MtSDH 
structural features and a framework for rational design of inhibitors based on initially 
characterized compounds. 
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NOMENCLATURE 
 
3DHS 3-dehydroshikimate 
A Alanine 
Ala Alanine 
Asn Asparagine 
Asp Aspartate 
D Aspartate 
DMSO Dimethyl sulfoxide 
DSF Differential scanning fluorimetry 
DTT Dithiothreitol 
G Glycine 
Gln Glutamine 
Gly Glycine 
I Isoleucine 
Ile Isoleucine 
IPTG Isopropyl-β-D-1-thio-galactopyranoside 
K Lysine 
L Leucine 
Leu Leucine 
Lys Lysine 
M Methionine 
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Met Methionine 
Mtb Mycobacterium tuberculosis 
N Asparagine 
NAD
+
 Nicotinamide adenine dinucleotide 
NADP
+
 Nicotinamide adenine dinucleotide phosphate 
NADPH Nicotinamide adenine dinucleotide phosphate reduced 
PCR Polymerase chain reaction 
PMSF Phenylmethanesulfonyl fluoride 
Q Glutamine 
Rmsd Root mean square deviation 
S Serine 
SAD Single-wavelength anomalous diffraction 
SDH Shikimate dehydrogenase 
Ser Serine 
SKM Shikimate 
TB Tuberculosis 
Tyr Tyrosine 
Val Valine 
Y Tyrosine 
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1. INTRODUCTION  
 
Mycobaterium tuberculosis (Mtb) is the main causative agent of tuberculosis 
(TB) disease resulting in loss of many human lives. It has been one of the most 
successful human pathogens, evident from the fact that one-third of the human 
population is estimated to be currently infected with latent TB (1). Each year 8 million 
new cases of Mtb infection are reported, of which 5-10% of the patients will potentially 
develop active TB in their lifetime. TB continues to claim more than 1.5 million lives 
annually and is a major concern for human health, because it is a contagious airborne 
disease. In 1940s and 50s, streptomycin, isoniazid, rifampicin, ethambutol and 
pyrazinamide were introduced as front line drugs and to date continue to be used 
effectively as primary anti-tubercular drugs. However, the long duration of the drug 
regimen has in some cases resulted in incomplete therapy. Consequently, the evolution 
of single-drug resistant (SDR), multi-drug resistant (MDR) and extensive-drug resistant 
(XDR) (2) strains of Mtb has exacerbated the problem. Therefore, there is an urgent need 
to develop new and effective drugs against Mtb to pre-empt the re-emergence of 
pandemic TB. One of the modern approaches to developing new drugs for diseases 
entails identification of suitable molecular targets. The availability of complete genome 
sequence of Mtb (3) has led to identification, testing and validation of molecular 
targets/pathways for development of new anti-mycobacterial compounds. 
The shikimate pathway plays a fundamental role by linking carbohydrate 
metabolism to the biosynthesis of aromatic compounds in bacteria, fungi, plants and 
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apicomplexan parasites (4, 5). The pathway begins with utilization of 
phosphoenolpyruvate and erythrose 4-phosphate through a series of seven enzymatic 
steps to yield chorismate, a critical precursor incorporated during biosynthesis of 
aromatic amino acids, folates and ubiquinones (4). The absence of this pathway in 
metazoans renders it an attractive target for inhibitor development with applications as 
anti-microbials, herbicides and anti-parasitic agents with low mammalian toxicity. The 
widely used broad spectrum herbicide glyphosate is known to inhibit 5-
enolpyruvylshikimate-3-phosphate (EPSP) synthase (6, 7), sixth enzyme of the pathway, 
providing evidence that this pathway is validated for inhibitor development with 
practical utility. In Mtb, this pathway has been shown to be essential for cell viability, 
despite addition of supplements in relation to the pathway (8). 
Shikimate dehydrogenase (SDH) is the fourth enzyme in the shikimate pathway 
and belongs to a family of NAD(P)H-dependant oxidoreductases (EC 1.1.1.25). The 
enzyme catalyzes the reversible reduction of 3-dehydroshikimate (3DHS) to shikimate 
(SKM) utilizing NADPH cofactor (Figure 1). 
 
 
Figure 1. Reaction catalyzed by shikimate dehydrogenase (SDH). 
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SDH exists in many bacteria as a single functional polypeptide, and in organisms 
like fungi and yeast, the enzyme is part of a multidomain pentafunctional enzyme 
catalyzing steps two to six of the shikimate pathway (9, 10). In plants, SDH is fused with 
3-Dehydroquinate dehydratase, the third enzyme of shikimate pathway (11, 12). The 
homologs of SDH family display distinct biochemical functions, share low sequence 
identity, yet are structurally conserved. Within the five distinct classes, AroE is an 
archetypal SDH class found in most microbial organisms, using 3DHS / SKM as 
substrate and NADPH / NADP
+
 as cofactor (13, 14). YdiB class is a bifunctional 
reversible quinate/shikimate dehydrogenase with dual specificity for substrate (quinate 
and shikimate) and cofactor (NAD
+
 and NADP
+
) (15), occurs less widely in microbial 
organisms and is primarily implicated in the catabolic quinate utilization as a sole carbon 
source for growth (16, 17), in a NAD
+
 dependent manner. The physiological roles of 
three other classes, shikimate dehyrogenase-like (SdhL), AroE-like1 (Ael1) and RifI2 
are unclear (18-20). Although, some microorganisms have paralogs of SDH encoding 
genes, Mtb genome analysis revealed a single gene aroE (Rv2552c), encoding SDH 
belonging to AroE class (3). The kinetic isotope and pH-rate profile studies of MtSDH 
propose that the hydride transfer and protonation of C3 group of 3DHS proceed in a 
concerted manner and that an amino acid with an apparent pKa of 8.9 is involved in the 
catalytic activity (21). The E. coli SDH is known to stereo-specifically transfer C4-proR 
hydride of NADPH (22), which is consistent with the evidence from crystal structure of 
binary complex with the cofactor (15). However, in case of MtSDH, it is reported that 
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the C4-proS hydride of NADPH is stereo-specifically transferred in the oxy-reduction 
reaction on 3DHS (21). There is a well established correlation between the mode of 
NADPH binding and stereo-specific transfer by oxidoreductases and the molecular basis 
of this difference in MtSDH is unclear due to lack of three-dimensional structural 
analysis. 
To date, crystal structures of SDH from 14 different species representing all five 
distinct classes have been determined and deposited in Protein Data Bank (PDB) (23). 
Structural analysis of AroE class of SDH describing the apo-enzyme, binary complex 
with substrate from Staphylococcus epidermidis SDH (SeSDH; PDB ID: 3DOO) (24) or 
cofactor from E. coli SDH (EcSDH; PDB ID: 1NYT) (15), inactive ternary complex 
from Aquifex aeolicus SDH (AaSDH; PDB ID: 2HK9_A) (25) and Thermus 
thermophilus SDH (TtSDH; PDB ID: 2EV9) (26) and an active ternary complex from 
AaSDH (PDBID: 2HK9_D) reveal conformational flexibility that manifest in open and 
closed forms of the enzyme. This conformational switch is linked to the activity of the 
enzyme, where the closed form is believed to be catalytically active form.  
In this thesis, the crystal structures of MtSDH apo-enzyme and binary complex 
with SKM are reported. Additionally, selected inhibitors of MtSDH (Table 1) identified 
previously from a high-throughput enzyme assay screen are evaluated and characterized. 
The study provides a structural framework for efforts in rational design of inhibitors 
against MtSDH. 
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Table 1. Selected inhibitors of MtSDH. 
 
Compound ID Structure Name 
2 EN:T0509-3962 
 
 
5-chloro-7-
(morpholino(thiophen-2-
yl)methyl)quinolin-8-ol 
5 EN:T0512-3612 
 
 
1-(4-bromophenyl)-1-
methyl-1H-
[1,2,4]triazino[5,4-
b]quinazolin-10(2H)-one 
6 EN:T0514-6228 
 
 
2-(1H-benzo[d]imidazol-
2(3H)-ylidene)-3-oxo-4-(5-
(3-
(trifluoromethyl)phenyl)-
2H-tetrazol-2-
yl)butanenitrile 
8 EN:T5232146 
 
 
1-(1H-benzo[d]imidazol-2-
yl)-3-(3,4-
dichlorophenyl)urea 
11 EN:T5690368 
 
 
2-(1,1-dioxido-2H-
naphtho[1,8-cd]isothiazol-
2-yl)-N-(5-methylthiazol-2-
yl)acetamide 
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2. EXPERIMENTAL PROCEDURES 
 
2.1 Cloning, protein over-expression and purification 
MtSDH encoding gene AroE (Rv2552c) was amplified by polymerase chain 
reaction (PCR) from the genomic DNA of Mtb H37Rv. The purified PCR product was 
digested and ligated with pET-30b expression vector (Novagen) at NdeI and XhoI 
restriction sites. The stop codon of the gene was excluded on the anti-sense primer to 
incorporate the vector encoded His-tag, resulting in a C-terminal His-tagged MtSDH. 
The following primers were used: 
Sense primer 
 5'-ATACTTCATATGAGCGAAGGTCCCAAAAAAGCCGG-3' and  
Anti-sense primer 
5'- ATACTTCTCGAGGTCCAACGCGGCCAGCG-3' 
The sequence of the coding region in MtSDH-pET30b expression construct was 
confirmed by DNA sequencing. 
 The MtSDH-pET30b expression construct was transformed into E. coli BL21 
(DE3) over-expression strain (Novagen). The cell culture was grown at 18 °C in Terrific 
Broth media containing kanamycin 50 µg/mL (for selection) until the mid-log phase 
(OD600 = 0.6-0.8) and immediately incubated in ice cold water for 30-45 minutes. Over-
expression of MtSDH was induced by addition of 1 mM isopropyl-β-D-1-thio-
galactopyranoside (IPTG) to ice cold cell culture and grown at 18 °C overnight. The 
cells were harvested and resuspended in 50 mM Tris-HCl pH 7.5, 300 mM NaCl and 2 
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mM β-mercaptoethanol (buffer A) containing 20 µg/mL DNase I, 2mM MgCl2 and 
1mM PMSF. The cells were lysed in M-110P Microfluidizer
®
 processor at an operating 
pressure of 18,000 psi. The lysate was centrifuged at 30,000 × g for 45 min at 4 °C and 
the clarified extract was filtered with 0.2 µm syringe filter and loaded on HisTrap FF 
column (GE Healthcare Life Sciences), pre-equilibrated with Buffer A containing 20 
mM imidazole (buffer B). After loading the lysate, the column was washed with 5 
column volumes of buffer B, followed by 10 column volumes of buffer A containing 40 
mM imidazole (buffer C). The protein was eluted with a gradient of 40-500 mM 
imidazole in buffer A. The fractions containing MtSDH were pooled and concentrated 
using Spin-X
®
 UF (Corning
®
) concentrator. This concentrated protein was loaded on 
HiLoad 26/60 Superdex 200 prep grade (GE Healthcare Life Sciences) gel filtration 
column, pre-equilibrated with 10 mM Tris-HCl pH 7.5, 300 mM NaCl and 1 mM DTT 
(buffer D). The eluted protein was pooled and concentrated to 10 mg/mL for 
crystallization. Based on 4-12 % gradient SDS-PAGE gel (Bio-Rad), MtSDH was more 
than 95 % homogeneous. All protein purification and concentrating procedures were 
performed in 4 °C. 
 
2.2 Crystallization, data collection and processing 
Crystallization was performed by vapor diffusion method in sitting drop plates at 
18 °C.  Crystals were obtained for MtSDH (10 mg/mL) in presence of 500 µM SKM in 
the condition containing 0.08 M sodium citrate pH 6.2, 1.54 M (NH4)2SO4, 2.7 % 1,6-
hexanediol and 0.1 M guanidine HCl. Crystals grew to maximum size in 15-20 days in 
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drops mixed with 0.4 µL protein mixture (MtSDH + SKM) and 0.4 µL of crystallization 
condition. Based on this crystallization condition, optimization was performed to obtain 
crystals for apo-MtSDH. The apo-MtSDH (10 mg/mL) crystallized in 0.1 M sodium 
citrate pH 6.2, 1.65 M (NH4)2SO4, 2.7 % 1,6-hexanediol and 0.1 M guanidine HCl by 
vapor diffusion technique, mixing 0.4 µL protein with 0.4 µL of crystallization buffer in 
sitting drop plates at 18 °C and grew to maximum size in 15-20 days. Prior to data 
collection, the crystals were transferred to a cryoprotectant composed of 15 % glycerol 
in mother liquor for 15-20 seconds and immediately flash frozen in liquid nitrogen. 
Bromide-derivative crystals were prepared by soaking MtSDH-SKM co-crystal in 
cryoprotectant solution containing 1 M NaBr for 10 minutes. The crystals for MtSDH-
shikimate complex were obtained by soaking MtSDH-SKM co-crystal in mother liquor 
containing 5 mM SKM for 30 minutes and transferred to cryoprotectant solution before 
flash freezing in liquid nitrogen. 
Data sets were collected on beamlines 23-ID of General Medical Sciences and 
Cancer Institutes Structural Biology Facility and 19-ID of Structural Biology Center, 
Advanced Photon Source (APS), Argonne National Laboratory (ANL). For the bromide-
derivative crystal, 720 frames were collected in 0.5° oscillation steps with 1sec exposure 
per frame at a wavelength of 0.92 Å, which is close to the absorption edge of bromine. A 
total of 120 and 240 frames were collected in 1° oscillation steps with 1 sec exposure per 
frame at a wavelength of 0.98 Å for the data sets of apo-MtSDH and MtSDH-shikimate 
complex crystals, respectively. Diffraction data was indexed, integrated and scaled using 
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HKL-2000 program package (27). Relevant statistics of data collection and processing 
are summarized in Table 2. 
 
2.3 Structure solution and model refinement 
Phase determination by single-wavelength anomalous diffraction (SAD) method 
was performed for bromide derivatized MtSDH – SKM cocrystal  using AutoSol in 
PHENIX (28) software suite.  The apo-MtSDH and MtSDH – SKM complex structure in 
P 21 21 2 space group was determined by molecular replacement method using AutoMR 
in PHENIX and with one MtSDH molecule as a starting model. Manual model building 
of missing residues and side chains from the initial model was carried out using Coot 
(29); and phenix.refine in PHENIX was used for refinement. The quality of all structural 
models were assessed with PROCHECK (30) and MolProbity (31). Figures and 
superpositions of structural models were generated using Chimera (32). The refinement 
statistics are summarized in Table 2. 
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Table 2. Summary of diffraction data and refinement statistics. 
 
 Apo-MtSDH Shikimate-MtSDH Bromide-MtSDH 
Data Collection    
   Space group P 21 21 2 P 21 21 2 P 21 21 21 
   Cell dimensions    
      a, b, c (Å) 128.57, 132.70, 38.61 129.70, 132.31, 38.46 43.47, 75.55, 129.71 
      α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 
   Wavelength (Å) 0.979 0.979 0.920 
   Resolution (Å) 50.0-1.95 (1.98-1.95) 50.0-2.03 (2.08-2.03) 50.0-1.70 (1.73-1.70) 
   Completeness (%) 99.30 (98.68) 98.42 (89.36) 99.47 (95.13) 
   Redundancy 4.4 (4.2) 9.0 (8.9) 7.3 (4.4) 
   I / Iσ 24.92 (8.81) 20.12 (2.62) 25.63 (4.38) 
   Rsym 0.057 (0.175) 0.066 (0.733) 0.088 (0.608) 
Refinement    
   Resolution (Å) 46.17-1.95 46.31-2.03 49.23-1.70 
   No. of reflections 49154 42809 47232 
   Rwork / Rfree 0.186 / 0.228 0.202 / 0.248 0.184 / 0.228 
   No. of Atoms    
      Protein 5614 5596 3743 
      Ligand / ion 25 73 34 
      Water 346 102 495 
   B-factors (Å
2
)    
      Protein 22.7 48.1 16.6 
      Ligand / ion 27.6 44.4 28.0 
      Water 27.5 39.8 33.2 
   Rmsd    
      Bond length (Å) 0.007 0.008 0.006 
      Bond angles (°) 1.12 1.14 1.10 
   Ramachandran plot    
      Most favored (%) 96.0 95.0 95.1 
      Allowed (%) 4.0 5.0 4.9 
      Disallowed (%) 0 0 0 
Values in parentheses are for highest resolution shell. 
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2.4 Differential scanning fluorimetry 
Thermal profile of MtSDH was investigated in presence of substrates and 
inhibitors. In a 96-well thin wall PCR plate, the protein was diluted to a final assay 
concentration of 10 µM in 100 mM potassium phosphate buffer pH 7.4, 5× SYPRO
®
 
orange dye (Life Technologies) and 2.5% (v/v) DMSO. The final concentration of 3DHS 
and NADPH was 500 µM and stock solutions of compounds prepared in DMSO were 
diluted to 300 µM in the final assay volume of 20 µL. All measurements were taken in 
duplicate. After adding all the components, the PCR plate was centrifuged at 1500 rpm 
for 2 minutes and sealed with an optical quality adhesive film. Thermal denaturation was 
recorded using Mx3005P qPCR system (Agilent Technologies), with excitation and 
emission wavelengths of 492 nm and 610 nm, respectively, for SYPRO orange, applying 
a temperature gradient of 1 °C/min from 25 °C to 75 °C. The midpoint temperature of 
protein thermal melting, Tm, was determined by fitting the base-line corrected raw 
fluorescence (dR) data to the Boltzmann sigmoid equation using GraphPad Prism 6 
(GraphPad Software, Inc.). Fitting of data was judged from the goodness of fit (R
2
 > 
0.98). 
 
2.5 MtSDH enzymatic assays 
The MtSDH enzyme activity was assayed in 100 mM potassium phosphate 
buffer pH 7.4 containing final concentration of 0.5% (v/v) DMSO, by monitoring the 
oxidation of NADPH at 340 nm (ε340 = 6220 M
-1
 cm
-1
) in the presence of 3DHS at 25 °C 
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in a final assay volume of 1 mL, with disposable acrylic cuvettes. The kinetic data were 
collected on Cary 100 UV-Vis spectrophotometer (Agilent Technologies) in triplicates. 
The initial velocities of enzyme activity were measured by titrating substrate (3DHS) or 
cofactor (NADPH), in presence of saturating concentration of the other. The reaction 
was initiated by addition of NADPH. 
To investigate the dose-dependent inhibition effect, 8 nM of enzyme was 
incubated with compounds at concentrations of 0, 0.5, 1, 2, 4, 8, 16, 32, and 64 µM for 
10 minutes before starting the reaction in presence of 40 µM 3DHS (2× times its Km)  
and 150 µM NADPH (15× times its Km). The IC50 values were derived by fitting the 
initial velocity data to a sigmoid dose-response equation in SigmaPlot™ 12.5 package 
(Systat Software, Inc.). 
To investigate the mode of inhibition, substrate and cofactor were titrated in 
presence of saturating concentration of the other, at varied compound concentrations. 
3DHS was titrated in the concentrations of 15, 30, 60, 120, and 240 µM while NADPH 
was maintained at 200 µM. NADPH was titrated in the concentrations of 5, 10, 20, 40, 
and 80 µM while 3DHS was maintained at 200 µM. Initial velocities were measured 
with compounds 2, 6 and 8 varied at concentrations of 0, 3, 4.5, and 6 µM, whereas with 
compounds 5 and 11 concentrations were varied at 0, 2, 3.5 and 5 µM. The kinetic 
parameters, Michaelis constants, Km, and maximal rates, Vmax, were derived by fitting 
data to Michaelis-Menten equation and was judged from the goodness of fit (R
2
 > 0.98). 
SigmaPlot™ 12.5 (Systat Software, Inc.) was used for all kinetic data analysis and plots. 
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3. RESULTS AND DISCUSSION 
 
3.1 Structure determination of MtSDH 
Three dimensional co-crystals of MtSDH-SKM were optimized and bromide 
derivatives were produced by soaking them for 10 minutes in cryoprotectant solution 
containing 1 M NaBr. Bromide-SAD data was collected to 1.7 Å resolution and the 
crystal belonged to primitive orthorhombic space group P 21 21 21 containing 2 
molecules in an asymmetric unit with solvent content of ~28%. The anomalous signal 
was significant to ~2.2 Å.  Substructure solution using PHENIX (28) AutoSol initially 
located 67 bromide sites with a figure of merit (FOM) of 0.39. A partial preliminary 
model was subjected to iterative model building and refinement with AutoBuild, which 
automatically built 470 residues and 334 side chains with Rwork and Rfree values of 29.3 % 
and 32.6 %, respectively. This model was subsequently refined with few rounds of 
noncrystallographic symmetry restraints using phenix.refine. Missing residue side chains 
were built manually into 2Fo – Fc and Fo – Fc electron-density maps and further refined. 
The final Rwork and Rfree was 18.4 % and 22.8 %, respectively. 
The density of shikimate in the bromide derivatized cocrystal of MtSDH-SKM 
was partial. Therefore, the cocrystal of MtSDH-SKM was soaked additionally for 30 
minutes in 5mM SKM, prepared in mother liquor and flash frozen with cryoprotectant 
before data collection. Data was collected to 2.03 Å resolution and the MtSDH-
shikimate binary complex crystal belonged to primitive orthorhombic P 21 21 2 space 
group containing 3 molecules in an asymmetric unit and a larger unit cell, different from 
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bromide derivatized crystal. An initial model of MtSDH-shikimate binary complex was 
obtained by molecular replacement method using AutoMR in PHENIX due to the 
difference in unit cell and space group. This model was subjected to iterative model 
building and refinement using AutoBuild, followed by rigid-body refinement and 
subsequent rounds of noncrystallographic symmetry restraints refinement using 
phenix.refine. Unambiguous density of shikimate was observed in difference Fourier 
maps in all 3 molecules of the asymmetric unit. The Rwork and Rfree of the final model 
was 20.2 % and 24.8 %, respectively. 
The optimized apo-MtSDH crystals diffracted to a resolution of 1.95 Å and 
belonged to primitive orthorhombic P 21 21 2 space group containing 3 molecules in an 
asymmetric unit and unit cell dimensions similar to MtSDH-shikimate binary complex 
crystal. The model of apo-MtSDH was obtained by refining data against the structure of 
MtSDH-shikimate (excluding ligand and heteroatoms) using phenix.refine. The final 
Rwork and Rfree of the apo-MtSDH was 18.6 % and 22.8 %, respectively. All the three 
structures’ stereochemistry was analyzed by PROCHECK and no outliers were seen in 
the Ramachandran plot. 
 
3.2 Overall structure of apo-MtSDH and binary complex with shikimate 
The structures were obtained in two crystal forms. The bromide soaked co-
crystal of MtSDH-shikimate binary complex was obtained in crystal form I (space group 
P21 21 21) with two crystallographically independent molecules per asymmetric unit, 
solved at 1.7 Å resolution. The apo-enzyme and co-crystal MtSDH-shikimate further 
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soaked with shikimate were obtained in crystal form II (space group P 21 21 2) with three 
crystallographically independent molecules per asymmetric unit, solved at 1.95 Å and 
2.03 Å resolution, respectively.  
The apo-MtSDH structure contains 788 amino acids (residues 5 – 268 for subunit 
A, 5 – 265 for subunit B, and 5 – 267 for subunit C), 5 sulfate ions and 346 water 
molecules. The binary structure of MtSDH-shikimate in crystal form I contains 525 
amino acids (residues 5 – 267 for subunits A and B, the loop containing residues 173 – 
177 is disordered in subunit B), one shikimate molecule in subunit A, 7 bromide ions, 3 
sulfate ions and 495 water molecules.  Whereas the crystal form II contains 784 amino 
acids (residues 5 – 267 for subunits A, B and C, residues117, 175 – 180 from subunit B 
and residue 118 from subunit C were not built due to lack of backbone density), three 
shikimate molecules, 5 sulfate ions and 102 water molecules. The shikimate molecules 
adopt half-chair conformation. In all crystal forms, strong density was found near 
Arg149, in which sulfate was fit in a satisfactory manner. 
The overall structure of MtSDH is modular with two structural domains 
containing α/β architecture (Figure 2), similar to other SDH structures. The N-terminal 
substrate binding domain is formed by two discontinuous segments composed of 
residues 5 – 108 and 241 – 267, containing six-stranded β-sheet in the order β2, β1, β3, 
β5, β6 and β4 with β5 strand being anti-parallel to other strands. Helices α1, α13 and α14 
flank these strands on one side and on the other side are helices α2, α3 and α4. The C-
terminal cofactor binding domain composed of residues 109 – 240 adopts a Rossmann 
fold containing six-stranded  parallel β-sheet in the order β9, β8, β7, β10, β11 and β12, 
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flanked by helices α6 and α7 on the inner side and α8, α9, η10 (310 helix), α11 and α12 
on the outer side. In other SDH structures, β10 and β11 strand are connected by a long 
loop. However, in MtSDH this loop is replaced by a series of α9, η10 and α11 helices. 
Between the two domains are interconnecting helices α5 and α13 forming a groove in 
which substrate and cofactor bind for catalysis. 
 
 
Figure 2. Overall structure of MtSDH. The structure is shown as cartoon. Secondary 
structural elements are colored as follows: helices in green, sheets in gold, loops in 
orchid. The ligands are colored by heteroatoms with carbons for SKM in yellow and in 
purple for NADP
+
 (modeled by superposition of Aquifex aeolicus SDH structure on 
MtSDH). 
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3.3 Conformational flexibility of MtSDH 
The conformational flexibility of SDH is observed and reported for different 
structures. The flexibility results in domain movements and manifests in various degrees 
of open and closed form of SDH, which is related to the activity of the enzyme. The 
crystal structures of both apo-MtSDH and MtSDH-shikimate binary complex are in a 
closed conformation when compared to other known open conformation of SDH 
homologs. The co-crystal structure in crystal form I is in a more closed conformation 
than the structures in crystal form II and this conformational difference in MtSDH is 
attributed to the hinge residues 
105
Asp-Ile-Asp
107
 and 
238
Gln-Met-Leu-Leu
241
 within the 
α-helices (α5 and α13) linking the two domains of the protein (Figure 3). The domain 
movements correspond to ~ 11° rotation around an axis passing through Cα of Asp105 
and Leu241. The backbone root mean square deviation (Rmsd) between the two 
conformations is 0.48 Å and 0.36 Å for N-terminal substrate binding domain and C-
terminal cofactor binding domain, respectively.  
Determined bond distances between some key residues in the substrate binding 
and cofactor binding sites are characteristic of the open and closed form of SDH (24). 
Among these are the distance between Cα of catalytic lysine and the invariant central 
glycine in Gly-Ala-Gly-Gly-Ala motif and the distance between Cα of conserved 
tyrosine and two serines in the substrate binding pocket. In MtSDH, the Cα of catalytic 
Lys69 and invariant Gly126 are at a distance of 8.9 Å, and the distance between Cα of 
conserved Tyr215 – Ser18 and Tyr215 – Ser20 are 9.1 Å and 11.5 Å, respectively 
(Figure 3). These bond distances are very similar to those observed in the closed active 
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ternary complex of AaSDH (25), in contrast to open conformation of SeSDH (24). 
Taken together, the MtSDH structure represents a closed conformation, equivalent to 
catalytically active form. 
 
 
Figure 3. Structural elements of MtSDH closed conformation. Superposition of MtSDH 
and SeSDH structures. Partial MtSDH is shown in white cartoon. The carbons 
corresponding to residues that show prominent movement between the MtSDH and 
SeSDH are highlighted in green and orchid colors, respectively. The SKM is colored 
according to the enzyme it is bound to. The distance between key residues that define the 
open or closed conformation, K69-G126, Y215-S18 and Y215-S20 in MtSDH are 
shown. The axis passing through D105 and L241 resulting in domain movement is 
shown in red broken arrow. The extent of shift in structural elements between MtSDH 
and SeSDH are indicated in black two-sided arrows. 
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3.4 Analysis of the substrate-binding domain 
The substrate binding domain is structurally well conserved in SDH enzymes. 
The SKM binding site is in a pocket formed between the N-terminal substrate binding 
domain and the C-terminal cofactor binding domain. In the binary structure of MtSDH, 
the density for SKM is unambiguous and adopts a half-chair conformation with the C3-
O bond positioned orthogonal to its ring system (Figure 4A). SKM is situated near β1, 
β3, β5 strands, α3 helix and interconnecting loops at the bottom and surrounded by α1, 
α13 and α14 helices on the top. The carboxylate group and three (C3, C4 and C5) 
hydroxyl groups of SKM interact with several residues in the pocket (Figure 4B). The 
carboxylate group makes hydrogen bonds with highly conserved side chains of Ser18-
OG (2.4 Å) and Ser20-OG (2.7 Å). Substitution of the first conserved serine has been 
shown to have significant effect on the affinity of substrate and substitution of the 
second conserved serine affected both affinity and catalysis in SDH from Arabidopsis 
thaliana (33). Pro14 and Pro21 are also highly conserved and may play a role in optimal 
positioning of the conserved serines to form stable interaction with the carboxylate of 
SKM. Tyr215 is located in the cofactor binding domain, however its side chain extends 
into the SKM binding pocket allowing Tyr-OH (2.5 Å) to hydrogen bond with the 
carboxylate group of SKM. Although, Tyr215 is not catalytically involved, substitution 
has been shown to affect catalysis, suggesting its role in stabilizing the catalytic 
intermediate, rather than initial binding (24, 33). The C5-hydroxyl forms hydrogen bond 
with the side chains of Asn90-ND2 (3.5 Å) and Gln243-OE1 (3.1 Å). In some SDH 
homologs, hydrogen bonding is formed with an additional conserved Asn located near 
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the C5-hydroxyl, which is replaced with Ser63 in MtSDH and is too distant to form 
hydrogen bond. The C4-hydroxyl forms hydrogen bonds with the side chains of 
conserved Lys69-NZ (3.4 Å), Asn90-ND2 (2.9 Å) and Asp105-OD1 (2.6 Å). The C3-
hydroxyl is hydrogen bonded to Thr65-OG1 (2.9 Å) and conserved Lys69-NZ (2.9 Å). 
The presence of Pro67 probably assists in positioning the side chain of Lys69. Invariant 
residues corresponding to Lys69 and Asp105 of MtSDH are known to be absolutely 
essential for catalysis in AroE class of SDH. Interestingly, mutation of equivalent Lys 
and Asp residues in SdhL of H. influenzae and AroE of A. thaliana reduced activity to 
undetectable level (18, 33), whereas mutagenesis of these residues in E. coli YdiB 
indicated their role in substrate binding (34). 
 
 
Figure 4. Shikimate and its interactions with MtSDH. (A) Fo – Fc OMIT map of SKM 
contoured at 3σ level based on the final refined coordinates of MtSDH. (B) Specific 
interactions of the residue sidechains of MtSDH (carbons in green) and bound SKM 
(carbons in yellow) are shown in sticks and lines. 
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3.5 Analysis of the cofactor-binding domain 
Attempts to obtain MtSDH structures of binary complex with cofactor NADP(H) 
or the ternary complex with substrate and cofactor have been unsuccessful. Comparison 
of MtSDH sequence with other structurally characterized bacterial AroE class of SDH 
enzymes show less than 25% sequence identity, however, they share strong structural 
similarity. Structure based sequence alignment of SDHs allow the identification of well 
conserved cofactor binding motifs. A glycine rich loop, a “basic patch” and the 
nicotinamide binding residues form the structurally conserved NADP(H) binding motifs 
and are present in MtSDH. Although, there are small differences in the sequence motif 
of glycine rich loop and the basic patch, NADP
+
 could be reliably modeled in the 
binding site by superimposing with SDH homologous structures containing the cofactor. 
The ternary structure of AaSDH bound with shikimate and NADP
+
 (PDB ID: 2HK9, 
Chain D) represents a catalytically competent closed conformation of the enzyme (25).  
The NADP
+ 
was modeled into the co-crystal structure of MtSDH bound with 
SKM by superimposing with the ternary structure of AaSDH. Based on this model and 
analysis of conserved residues in the region, the positioning of NADP
+
 in the MtSDH 
structure offers insight into relevant enzyme-cofactor interactions (Figure 5). The 
carbonyl O7 atom of nicotinamide ring should form hydrogen bond with main chain 
nitrogen of Leu240, while the N7 atom of nicotinamide ring makes hydrogen bonds with 
main chain oxygen of Ala213 and invariant Gly236. These interactions are key in 
determining the mode of NADP(H) binding. This specific interaction between the 
cofactor and enzyme retains the nicotinamide ring in anti conformation with respect to 
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the ribose. The nicotinic ribose maintains mostly non-polar interactions with residues in 
the loop region between strand β11 and α12 helix.  
The motif of the glycine rich loop is typically composed of Gly-Ala-Gly-Gly-
Ala-Ala/Ser in most SDHs. However, the glycine rich loop of MtSDH, located between 
strand β7 and α6 helix is made up of 124Gly-Ser-Gly-Gly-Thr-Ala129 residues. The main 
chain nitrogen of Ser125 should form hydrogen bonds with the 3'-hydroxyl of adenine 
ribose while the main chain nitrogen of Gly127 and Thr128 form hydrogen bonds with 
the diphosphate moiety. The adenine group lies in the pocket facing its A-side to the 
“basic patch” and the B-side to residues from loop between strand β10 and α9 helix. The 
residues from the first turn in α9 helix are also involved in interactions. The consensus 
sequence of the “basic patch” motif is Asn-Arg-Thr-Xaa-Xaa-Arg/Lys and in MtSDH it 
is composed of residues 
148
Ala-Arg-Asn-Ser-Asp-Lys
153
, present within the preceding 
loop and part of α7 helix region. The residues interacting with the 2'-phosphate of 
adenine ribose are known to confer specificity for NADP(H) over NAD(H). In all the 
structurally characterized AroE class of SDH, adenosine 2'-phosphate interacts 
exclusively with the basic patch residues, primarily with side chains of invariant Arg 
(P2) along with Asn (P1) or/and Arg/Lys (P6). In some structures, additional bonding 
with side chain of Thr (P3) provides stability to phosphate binding. In our model, there is 
steric clash of adenine ring with the residues in the pocket on both sides. Therefore, 
these residues would have to move to accommodate the adenine ring in the pocket. In 
MtSDH, the α9, η10 and α11 helices facing the B-side of adenine ring replace a long 
loop found in all the other SDH structures solved to date. It is possible that this region 
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may undergo structural change upon NADP(H) binding. Similarly, the residues in the 
basic patch may rearrange on the A-side of the adenine to accommodate the plausible 
cation – π interaction and hydrogen bonding interaction of Arg149 side chain with the 
adenine ring and adenosine 2'-phophate, respectively. In fact, the electron density in this 
region is weak, suggesting the mobility of residues in absence of NADP(H).  
In MtSDH structure, a sulfate ion was fit into electron density very close to 
Arg149 in a satisfactory manner, which potentially corresponds to positioning of 
adenosine 2'-phosphate. In the model Arg149 and Asn150 from the basic patch are 
indeed within hydrogen bonding distance for interactions with 2'-phosphate of adenine 
ribose. Additionally, the side chain of Ser125-OG atom in the glycine rich loop is within 
hydrogen bonding distance of adenosine 2'-phosphate. Together Arg149, Asn150 and 
Ser125 could recognize the terminal phosphate moiety and reveal a novel cofactor 
binding microenvironment in SDH family of enzymes. 
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Figure 5. Interactions of MtSDH with shikimate and NADP
+
. The MtSDH residues, 
SKM and modeled NADP
+
 carbons are colored in green, yellow and purple, 
respectively. Only selective residue side chains interacting with SKM or NADP
+
 are 
shown for clarity. 
 
 
3.6 Mode of substrate and cofactor-binding, recognition and catalysis 
The binary complex crystal structure of MtSDH with shikimate in crystal form I 
represents a closed conformation. The NADP
+
 modeled into the binary complex of 
MtSDH – SKM by superimposition with the ternary structure of AaSDH bound with 
SKM and NADP
+
 allows for detailed understanding of the interactions and their 
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implication in enzyme catalysis. An earlier study reporting the kinetic and chemical 
mechanism of MtSDH proposed an ordered bi-bi mechanism with initial binding of 3-
dehydroshikimate followed by NADPH, consequently transferring the C4-proS hydride 
from NADPH and proton from an amino acid residue with an apparent pKa of 8.9 in a 
concerted manner (21). Subsequently, site-directed mutagenesis study showed that 
Lys69 is a critical residue for catalysis (35). A common proposition in the reaction 
catalyzed by SDH is the role of invariant lysine and aspartate forming catalytic dyad, 
functioning in a general acid-base mechanism during catalysis.  
It is evident from the binary structure of MtSDH with SKM that these 
corresponding residues, Lys69 and Asp105 are in close proximity of the reactive C3-
hydroxyl of SKM. In addition, based on the ternary model of MtSDH, C4 of the 
nicotinamide ring from cofactor is positioned within 3.5 Å distance to receive hydride 
from C3 of SKM. Based on MtSDH crystal structure and biochemical literature, it could 
be suggested that Lys69 side chain acts as an acid/base catalytic group donating a proton 
to 3DHS during the reduction reaction and removing a proton from SKM in the 
oxidation reaction, while Asp105 may play an important role in both substrate binding 
and catalysis by mediating proton transfer between Lys69 and a conserved water 
molecule found in many homologous SDH structures. 
It is well established that the hydride transfer catalyzed by oxidoreductases is 
stereo-specific and correlated to the binding mode of cofactor. The key determinant of 
cofactor conformation is the interaction of the amide group of nicotinamide ring with the 
protein to orient it in anti or syn conformation, and accordingly transfer pro-R or pro-S 
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hydride, respectively. It has been shown that E. coli SDH transfers the C4-proR hydride 
(A-side) of NADP(H) (22), consistent with anti conformation of the cofactor in the 
crystal structures. Whereas, similar biochemical studies on MtSDH indicate the transfer 
of C4-proS hydride (B-side) from NADPH in the oxy-reduction reaction (21), 
suggesting that cofactor will bind to the enzyme in syn conformation. However, the 
evidence from binary MtSDH crystal structure with SKM and modeled NADP
+
 
demonstrates that the cofactor would bind in anti conformation and consequently 
transfer C4-proR hydride (A-side). It could be hypothesized, that the cofactor may bind 
in different modes in oxidation and reduction states. Such observations have been made 
in crystal structures of UDP-glucose-4-epimerase and GDP-fucose synthetase enzymes 
from E. coli, but it was observed that the orientation of the nicotinamide ring with 
respect to ribose is dependent on the presence or absence of substrate (36-38). In 
MtSDH, the presence of substrate would confine the cofactor binding in anti mode to 
transfer C4-proR hydride (A-side), while the enzyme maintains a closed conformation 
during catalysis. In the event, the cofactor assumes syn conformation, there will be steric 
clash with the substrate. In order to avoid the clash and accommodate the cofactor in syn 
conformation the substrate would have to move; which will consequently require 
opening of the active site exposing it to the bulk solvent and the redox reaction is 
unlikely to occur under such conditions. 
 
 
 
 27 
 
3.7 MtSDH thermal denaturation profiles with substrates and inhibitors 
To test the binding of MtSDH inhibitors, identified previously from high-
throughput screening, thermal shift or differential scanning fluorimetry (DSF) assay was 
performed. A list of selected inhibitors is shown in Table 1. Thermal profile of MtSDH 
denaturation was assessed by following the fluorescence change of environmentally 
sensitive SYPRO Orange dye (Figure 6). The apo MtSDH showed a monophasic 
transition with a melting point, Tm of 57.38±0.03 °C. This condition allowed thermal 
profiling of MtSDH with substrates and inhibitors (Table 3). The Tm shift of protein in 
presence of substrates or compounds is indicative of binding interactions with the ligand. 
In most cases, the ligand binding stabilizes the protein thus making a positive shift in Tm. 
However, a ligand interaction could de-stabilize the protein, shifting the Tm negatively. 
The Tm shift of MtSDH in the presence of 3DHS and NADPH was 1.3 °C and 2.4 °C, 
respectively. While the Tm shift was 5.6 °C in presence of both 3DHS and NADPH, 
suggesting that substrate and cofactor binding provide more stability to MtSDH.  
Thermal denaturation of MtSDH was done with the inhibitors. Compounds 2, 6, 
8 and 11 showed significant Tm shift compared to controls (apo enzyme, in presence of 
3DHS, NADPH and in presence of both 3DHS and NADPH). There was no significant 
Tm shift observed for compound 5 under the performed assay conditions. The Tm of 
MtSDH increased with compound 6 and 11 by 4.8 °C and 2 °C, respectively. Whereas 
the Tm of MtSDH decreased with compound 2 by 13.0 °C, indicating that these 
compounds have binding interactions with MtSDH. The Tm with compound 2 in 
presence of 3DHS or NADPH did not vary significantly compared to free enzyme. 
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However the presence of both substrate and cofactor was able to counter the 
destabilizing effect of the compound. Compound 6 showed more Tm shift of MtSDH, 
compared to Tm shift in the presence of substrate or cofactor, indicating it can bind better 
to free enzyme than the enzyme-substrate/cofactor complex. The Tm of MtSDH in the 
presence of compound 8 could not be determined because the melting point transition 
was not monophasic. The Tm shift with Compound 11 was similar for free enzyme and 
in the presence of 3DHS compared to presence of NADPH. 
 
Table 3. Transition melting point, Tm of MtSDH. Tm determined from non-linear 
regression fit to Boltzmann sigmoidal equation.  
 
 
DMSO 
Control 
Compound 
2 5 6 11 
AroE 
 
 
57.38 °C 
±0.03 
 
44.34 °C 
±0.1 
 
57.50°C 
±0.1 
 
62.13 °C 
±0.08 
 
59.35 °C 
±0.05 
 
AroE +  3DHS 
 
58.7 °C 
±0.08 
 
42.82 °C 
±0.1 
 
59.09 °C 
±0.15 
 
62.87 °C 
±0.07 
 
62.25 °C 
±0.2 
 
AroE + NADPH 
 
59.76 °C 
±0.08 
 
44.18 °C 
±0.1 
 
59.07 °C 
±0.07 
 
63.16 °C 
±0.07 
 
61.68 °C 
±0.07 
 
AroE + 3DHS + NADPH 
63.0 °C 
±0.06 
 
49.88 °C 
±0.15 
 
63.15 °C 
±0.1 
 
65.7 °C 
±0.1 
 
64.92 °C 
±0.12 
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Figure 6. Thermal denaturation profile of MtSDH. (A) MtSDH ( ), +3DHS ( ), +NADPH ( ), +3DHS+NADPH ( ); (B) 
MtSDH ( ), +Compound 2 ( ), +Compound 5 ( ), +Compound 6 ( ), +Compound 11 ( ); (C) Thermal stability dependence 
of MtSDH on substrates and inhibitors (Bar colors same as in B).
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3.8 MtSDH initial velocity studies and evaluation of inhibitors 
Catalytic properties of MtSDH were investigated in the direction of formation of 
SKM and NADP
+
. The apparent Km for 3DHS and NADPH were determined to be 
21.3±0.5 µM and 9.6±0.6 µM, respectively, similar to previously reported values (39). 
MtSDH catalyzed the reduction of 3DHS at a maximal rate, Vmax, of 64.1±0.4 µmol min
-
1
 mg
-1
 with a catalytic constant, kcat, of about 29 sec
-1
 and at catalytic efficiency, kcat/Km 
of 1.4 x 10
6
 M
-1
 sec
-1
. Whereas the oxidation of NADPH was catalyzed at a maximal 
rate, Vmax, of 68.6±1.3 µmol min
-1
 mg
-1
 with a catalytic constant, kcat, of about 31 sec
-1
 
and at catalytic efficiency, kcat/Km of 3.3 x 10
6
 M
-1
 sec
-1
. 
Dose-dependent inhibition of MtSDH inhibitors (Figure 7) was evaluated. All the 
five compounds inhibited MtSDH at low micromolar concentrations. The IC50 values for 
compounds 2, 5, 6, 8 and 11 were 3.2±0.4 µM, 3.0±0.2 µM, 4.6±0.3 µM, 3.9±0.4 µM 
and 2.8±0.1 µM, respectively. 
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Figure 7. Dose-dependent inhibition of MtSDH. Compound 2 ( ), 5 ( ), 6 ( ), 8 ( ), 
and 11 ( ). 
 
 
The mode of inhibition was explored by determining the dependence of MtSDH 
activity on 3DHS and NADPH concentrations, in the absence and presence of inhibitors 
(Tables 4 and 5). Titration with 3DHS, affected the Vmax of MtSDH by decreasing it by ~ 
40% against compounds 2, 5 and 8, whereas with compounds 6 and 11, it decreased by 
~45% and 50%, respectively, at highest concentrations tested. Concurrently, the apparent 
Km of 3DHS increased in presence of all the compounds. Consequently, the effect on 
catalytic efficiency, kcat/Km, of MtSDH was observed with all the compounds. 
Compounds 2 and 8 decreased the efficiency to 0.5×10
6
 M
-1
 sec
-1
, about 3-fold 
compared to control. Whereas compounds 5 and 11 decreased the efficiency to 0.6×10
6
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M
-1
 sec
-1
 and 0.4×10
6
 M
-1
 sec
-1
, respectively. For the concentrations tested, compound 6 
showed most effect, decreasing efficiency to 0.3×10
6
 M
-1
 sec
-1
, more than 4-fold 
compared to control. 
Similarly, when titrating with NADPH, the Vmax of MtSDH decreased while there 
was a concomitant increase in the apparent Km in presence of compounds, consequently 
also reducing the catalytic efficiency of MtSDH. For the concentrations tested, the 
catalytic efficiency, kcat/Km, was affected most in the presence of compounds 5 and 11, 
reducing it to 0.7×10
6
 M
-1
 sec
-1
, more than 5-fold compared to control. Whereas 
compounds 6 and 8 reduced the efficiency to 0.9×10
6
 M
-1
 sec
-1
 and 1.0×10
6
 M
-1
 sec
-1
, 
respectively. Compound 2 was least effective, reducing the efficiency of MtSDH to 
1.1×10
6
 M
-1
 sec
-1
. The effects on Km and reaction’s Vmax suggest that the tested 
compounds act in non-competitive or mixed mode of inhibition with respect to both 
substrate and cofactor. 
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Table 4. MtSDH inhibition kinetics toward 3DHS titration. 
 
Compound 
 
Conc. 
(µM) 
Km 
(µM) 
Vmax 
(µmol min
-1
 mg
-1
) 
kcat 
(sec
-1
) 
kcat / Km 
(× 10
6
 M
-1
 sec
-1
) 
3DHS 
control 
 21.3±0.5 64.1±0.4 29.1±0.2 1.4 
2 
3.0 26.8±1.5 51.7±0.8 23.4±0.4 0.9 
4.5 32.4±2.3 44.7±1.0 20.3±0.5 0.6 
6.0 34.9±1.2 37.9±0.4 17.2±0.2 0.5 
5 
2.0 23.8±0.7 54.5±0.4 24.7±0.2 1.0 
3.5 30.7±2.0 47.2±0.9 21.4±0.4 0.7 
5.0 30.6±1.5 37.5±0.5 17.0±0.2 0.6 
6 
3.0 28.8±0.7 54.0±0.4 24.5±0.2 0.9 
4.5 29.7±0.4 47.5±0.2 21.5±0.1 0.7 
6.0 47.1±1.5 36.1±0.4 16.4±0.2 0.3 
8 
3.0 30.3±1.5 61.1±0.9 27.7±0.4 0.9 
4.5 33.2±1.8 46.5±0.8 21.1±0.4 0.6 
6.0 38.7±1.3 38.8±0.4 17.6±0.2 0.5 
11 
2.0 25.8±0.9 54.2±0.5 24.6±0.2 1.0 
3.5 29.8±2.7 44.0±0.9 20.0±0.4 0.7 
5.0 40.7±2.8 33.2±0.8 15.1±0.4 0.4 
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Table 5. MtSDH inhibition kinetics toward NADPH titration. 
 
Compound 
 
Conc. 
(µM) 
Km 
(µM) 
Vmax 
(µmol min
-1
 mg
-1
) 
kcat 
(sec
-1
) 
kcat / Km 
(× 10
6
 M
-1
 sec
-1
) 
NADPH  
control 
 9.6±0.6 68.6±1.3 31.1±0.6 3.3 
2 
3.0 14.0±2.2 67.0±3.6 30.4±1.6 2.2 
4.5 16.4±2.0 62.5±2.8 28.3±1.3 1.7 
6.0 18.7±2.0 43.5±1.7 19.7±0.8 1.1 
5 
2.0 14.4±2.3 60.2±3.3 27.3±1.5 1.9 
3.5 18.8±2.0 52.8±2.0 23.9±1.0 1.3 
5.0 25.4±4.5 36.8±2.6 16.7±1.2 0.7 
6 
3.0 14.5±1.5 60.2±2.0 27.3±0.9 1.9 
4.5 22.2±2.9 55.5±2.8 25.2±1.3 1.1 
6.0 25.4±1.7 52.8±1.5 23.9±0.6 0.9 
8 
3.0 8.4±0.9 61.6±1.8 27.9±0.8 3.3 
4.5 15.7±0.6 48.2±0.6 21.9±0.3 1.4 
6.0 16.4±2.4 36.8±1.9 16.7±0.9 1.0 
11 
2.0 11.5±0.4 48.0±0.6 21.8±0.3 1.9 
3.5 14.8±1.7 43.0±1.7 19.5±0.8 1.3 
5.0 15.5±1.5 24.6±0.8 11.2±0.4 0.7 
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Figure 8. Inhibition of MtSDH toward 3DHS with increasing concentration of compounds. (A) Compound 2 [0 µM ( ), 3 µM 
( ), 4.5 µM ( ), 6 µM ( )]; (B) Compound 5 [0 µM ( ), 2 µM ( ), 3.5 µM ( ), 5 µM ( )]; (C) Compound 6 [0 µM ( ), 3 µM 
( ), 4.5 µM ( ), 6 µM ( )]; (D) Compound 8 [0 µM ( ), 3 µM ( ), 4.5 µM ( ), 6 µM ( )]; (E) Compound 11 [0 µM ( ), 2 
µM ( ), 3.5 µM ( ), 5 µM ( )]. 
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Figure 9. Inhibition of MtSDH toward NADPH with increasing concentration of compounds. (A) Compound 2 [0 µM ( ), 3 
µM ( ), 4.5 µM ( ), 6 µM ( )]; (B) Compound 5 [0 µM ( ), 2 µM ( ), 3.5 µM ( ), 5 µM ( )]; (C) Compound 6 [0 µM ( ), 3 
µM ( ), 4.5 µM ( ), 6 µM ( )]; (D) Compound 8 [0 µM ( ), 3 µM ( ), 4.5 µM ( ), 6 µM ( )]; (E) Compound 11 [0 µM ( ), 
2 µM ( ), 3.5 µM ( ), 5 µM ( )]. 
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Table 6. Summary of MtSDH inhibition. 
 
Compound 
IC50  
(µM) 
3DHS titration NADPH titration 
Inhibition  
mode 
Ki  
(µM) 
αKi  
(µM) 
Inhibition  
mode 
Ki  
(µM) 
αKi  
(µM) 
2 3.2±0.4 mixed 3.1±0.5 8.7±0.3 non-competitive 8.5±1.4 - 
5 3.0±0.2 non-competitive 8.6±1.0 - non-competitive 5.2±0.8 - 
6 4.6±0.3 non-competitive 8.9±1.4 - mixed 2.2±0.3 15.9±0.8 
8 3.9±0.4 non-competitive 7.5±0.9 - non-competitive 7.1±1.4 - 
11 2.8±0.1 mixed 2.9±0.9 5.3±0.8 non-competitive 4.0±0.5 - 
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The data collected for titration of 3DHS and NADPH at different inhibitor 
concentrations were plotted as double-reciprocal plots displaying a series of intersecting 
lines (Figures 8 and 9). The kinetic data was fit to four possible modes of inhibition: 
competitive, noncompetitive, uncompetitive and mixed inhibition. The inhibition 
constants for the inhibitors were determined from the best fitting mode, summarized in 
Table 6. All the selected inhibitors showed best fit to non-competitive or mixed mode of 
inhibition and in both types of inhibition, the inhibitor is able to bind to free enzyme, 
forming enzyme-inhibitor (EI) complex, as well as the substrate bound enzyme, forming 
enzyme-substrate-inhibitor (ESI) complex. The inhibition constant, Ki, in a non-
competitive mode refers to the overall affinity of the inhibitor to free enzyme and 
enzyme-substrate complex. The mixed type of inhibition is a sub-type of non-
competitive inhibition, where inhibition constants, Ki and αKi, refer to the affinity of 
inhibitor to free enzyme and enzyme-substrate complex, respectively. When the value of 
α is greater than 1, the inhibitor has higher affinity to free enzyme, forming EI complex, 
than substrate bound enzyme, forming ESI complex. 
Kinetic analysis indicates that compounds 5, 6 and 8 are non-competitive 
inhibitors, whereas compounds 2 and 11 are mixed-type inhibitors with respect to 3DHS. 
Compound 2, 5-chloro-7-(morpholino(thiophen-2-yl)methyl)quinolin-8-ol and 
compound 11 containing naphthalene sulfonamide with thiazole subunit exhibited good 
potency with Ki of 3.1±0.5 µM and 2.9±0.9 µM and αKi of 8.7±0.3 µM and 5.3±0.8 µM, 
respectively. In the presence of 3DHS, the affinity to form ESI complex decreased more 
for compound 2 compared to compound 11.  On the other hand, compounds 2, 5, 8 and 
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11 are non-competitive inhibitors, whereas compound 6 is a mixed-type inhibitor with 
respect to NADPH. Compound 6 containing trifluoromethyl phenyl subunit was most 
potent with Ki of 2.2±0.3 µM and in the presence of NADPH the affinity, αKi increased 
to 15.9±0.8 µM. As shown in Table 1, these inhibitors exhibit different chemical 
scaffolds that can be modified for development of more potent inhibitors against 
MtSDH. 
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4. SUMMARY AND CONCLUSION  
 
Mtb is the etiological agent of tuberculosis disease and is on the verge of 
becoming a formidable health threat, due to emergence of single-drug resistant, multiple-
drug resistant and extensive-drug resistant strains against the first-line drugs, which have 
been in use since 1940s. Therefore, discovery of new antimycobacterial agents is 
imperative to counter re-emergence of tuberculosis. The availability of Mtb genomic 
information has enabled identification, testing and validation of molecular targets and 
pathways, suitable for inhibitor discovery and drug development. 
Shikimate pathway plays a central role by linking carbohydrate metabolism to 
biosynthesis of aromatic compounds in bacteria, fungi, plants and apicomplexan 
parasites. In Mtb, the genes involved in this pathway are shown to be essential for 
bacterial cell viability. SDH is the fourth enzyme of shikimate pathway catalyzing the 
reversible conversion of 3DHS to SKM utilizing NADP(H) cofactor. MtSDH is reported 
to stereo-specifically transfer C4-proS hydride of NADP(H) suggesting that the cofactor 
binds to enzyme in syn conformation, as opposed to well characterized homologs of 
SDH, which are known to stereo-specifically transfer C4-proR hydride while NADP(H) 
binds to enzyme in anti conformation. The molecular/structural basis of this difference 
has implications in development of MtSDH specific inhibitors and is not known due to 
lack of three dimensional structural analysis of MtSDH. 
In this study, the crystal structure of MtSDH was determined in the apo-form and 
in complex with SKM. The overall structure of MtSDH is modular; composed of N-
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terminal substrate binding domain with α/β architecture and C-terminal cofactor binding 
domain with Rossmann fold. The two modules are interconnected by two helices 
forming an active site groove where catalysis occurs. The structural variation in different 
crystal forms of MtSDH reported here, allowed the identification of hinge region located 
between the two structural modules in α5 and α13 helices and plays a significant role in 
open and closed conformation of the enzyme, which is linked to its activity. Structural 
comparison with SDH homologs reveal that in MtSDH a series of helices, α9, η10 and 
α11 connecting β10 and β11 strands replace a long loop and this region may undergo 
structural changes upon cofactor binding. Based on the MtSDH-shikimate complex 
structure, NADP
+
 was modeled reliably in the cofactor binding site. The analysis reveals 
that in addition to residues in “basic patch”, Ser125 within the glycine rich loop may 
interact with the 2'-phosphate of adenine ribose and form a novel cofactor binding 
microenvironment in SDH family of enzymes. Based on the model, it is clear that 
specific interactions between MtSDH and amide group of NADP(H)’s nicotinamide ring 
confers cofactor binding in anti conformation, which will result in stereospecific transfer 
of C4-proR hydride of NADPH as opposed to C4-proS hydride transfer as reported 
earlier. 
Biochemically, five inhibitors of MtSDH identified previously from a high-
throughput enzyme assay screen were characterized. The dose-dependent inhibition 
showed IC50 values of these compounds range from 2.8-4.6 µM. Inhibition mode was 
investigated and all the compounds displayed non-competitive or mixed inhibition mode 
with respect to substrate and cofactor. Compound 6, 2-(1H-benzo[d]imidazol-2(3H)-
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ylidene)-3-oxo-4-(5-(3-(trifluoromethyl)phenyl)-2H-tetrazol-2-yl)butanenitrile was most 
potent with Ki of 2.2±0.3 µM. Compound 2, 5-chloro-7-(morpholino(thiophen-2-
yl)methyl)quinolin-8-ol and compound 11, 2-(1,1-dioxido-2H-naphtho[1,8-
cd]isothiazol-2-yl)-N-(5-methylthiazol-2-yl)acetamide also exhibited good potency with 
Ki of 3.1±0.5 µM and 2.9±0.9 µM. 
This study is the first report of MtSDH crystal structure elucidating structural 
features to gain insight into specific interactions of enzyme with substrate and cofactor. 
The characterization of MtSDH inhibitors containing different chemical scaffolds along 
with the crystal structure lays the foundation for structure-guided design and 
development of MtSDH specific inhibitors with increased activity. 
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